口服抗凝药头部创伤患者临床相关迟发性颅内出血发生率极低:一项回顾性队列登记研究
该回顾性队列登记研究利用瑞典斯科讷地区急诊科两年数据(覆盖130万居民),纳入2362例口服抗凝药的成人头部创伤患者(中位年龄84岁,56%使用直接口服抗凝药),评估临床相关迟发性颅内出血的发生率和诊断时间。结果仅5例发生迟发性颅内出血,其中仅2例(0.08%,95%CI 0.01-0.3%)为临床相关(硬膜下血肿,年龄82岁和87岁,均 subsequent 死亡),诊断时间分别为就诊后4天和7天。作者认为该发生率不足千分之一且检出时间在4天及以后,对指南推荐的24小时观察期的有效性提出挑战,建议重新评估指南以优化护理和资源配置。
要点
- 2362例口服抗凝药头部创伤患者中,仅2例(0.08%,95%CI 0.01-0.3%)发生临床相关迟发性颅内出血。
- 临床相关迟发性颅内出血均在就诊4天及以后检出(分别为4天和7天),而非24小时内。
- 5例迟发性颅内出血中无1例接受神经外科手术或入住重症监护室。
- 作者认为24小时观察期的有效性受到挑战,建议重新评估斯堪的纳维亚神经创伤委员会指南。
适用人群与场景
- 成人头部创伤患者,且正在口服抗凝药治疗。
- 数据来自瑞典斯科讷地区急诊科,覆盖130万居民,为期两年。
诊断标准与关键阈值
- 迟发性颅内出血定义为初始头部CT扫描未见、后续30天内发现的颅内出血。
- 临床相关迟发性颅内出血定义为与死亡、任何重症监护室入住或神经外科手术相关的出血。
研究设计与关键结果
- 研究类型:回顾性队列登记研究;样本量2362例头部创伤病例;人群中位年龄84岁,56%使用直接口服抗凝药。
- 主要结果:5例发生迟发性颅内出血,其中仅2例(0.08%,95%CI 0.01-0.3%)为临床相关,均为硬膜下血肿,患者年龄82岁和87岁,均 subsequently 死亡。
- 迟发性颅内出血诊断时间分别为就诊后4天和7天。
- 5例迟发性颅内出血中无1例接受神经外科手术或入住重症监护室。
证据类型、等级与局限
- 证据类型:回顾性队列登记研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,口服抗凝药头部创伤患者临床相关迟发性颅内出血发生率不足千分之一,且检出时间在就诊4天及以后,对斯堪的纳维亚神经创伤委员会指南推荐的24小时观察期的有效性提出挑战,建议重新评估这些指南以优化护理和资源配置。
指南或共识出处
- 斯堪的纳维亚神经创伤委员会指南(Scandinavian Neurotrauma Committee guidelines)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guidelines from Scandinavian Neuro Committee mandate a 24-hour observation for head trauma patients on anticoagulants, even with normal initial head CT scans, as a means not to miss delayed intracranial hemorrhages. This study aimed to assess the prevalence, and time to diagnosis, of clinically relevant delayed intracranial hemorrhage in head trauma patients treated with oral anticoagulants.
METHOD: Utilizing comprehensive two-year data from Region Skåne's emergency departments, which serve a population of 1.3 million inhabitants, this study focused on adult head trauma patients prescribed oral anticoagulants. We identified those with intracranial hemorrhage within 30 days, defining delayed intracranial hemorrhage as a bleeding not apparent on their initial CT head scan. These cases were further defined as clinically relevant if associated with mortality, any intensive care unit admission, or neurosurgery.
RESULTS: Out of the included 2,362 head injury cases (median age 84, 56% on a direct acting oral anticoagulant), five developed delayed intracranial hemorrhages. None of these five cases underwent neurosurgery nor were admitted to an intensive care unit. Only two cases (0.08%, 95% confidence interval [0.01-0.3%]) were classified as clinically relevant, involving subdural hematomas in patients aged 82 and 87 years, who both subsequently died. The diagnosis of these delayed intracranial hemorrhages was made at 4 and 7 days following initial presentation to the emergency department.
CONCLUSION: In patients with head trauma, on oral anticoagulation, the incidence of clinically relevant delayed intracranial hemorrhage was found to be less than one in a thousand, with detection occurring four days or later after initial presentation. This challenges the effectiveness of the 24-hour observation period recommended by the Scandinavian Neurotrauma Committee guidelines, suggesting a need to reassess these guidelines to optimise care and resource allocation.
TRIAL REGISTRATION: This is a retrospective cohort study, does not include any intervention, and has therefore not been registered.
参考来源
- André L, Björkelund A, Ekelund U, et al. The prevalence of clinically relevant delayed intracranial hemorrhage in head trauma patients treated with oral anticoagulants is very low: a retrospective cohort register study. Scand J Trauma Resusc Emerg Med. 2024. PMID: 38730480. doi:10.1186/s13049-024-01214-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。